In a landmark policy unveiling that signals India’s ambitions to reshape the global life sciences landscape, Telangana Chief Minister A. Revanth Reddy inaugurated the “Next Gen Life Sciences Policy 2026–30” at BioAsia 2026, setting forth an audacious vision to position Hyderabad among the world’s top five life sciences hubs by 2030. The policy, part of the broader “Telangana Rising Vision 2047,” targets $25 billion in investments and 500,000 new jobs over the next four years, while charting a 22-year trajectory toward a $3 trillion state economy.
The Three-Ring Architecture: CURE, PURE, and RARE
The centerpiece of Telangana’s strategy is a regionally differentiated development model that Chief Minister Reddy described as ensuring “balanced and sustainable economic advancement” across urban, peri-urban, and rural zones. This three-ring architecture represents a departure from traditional metropolitan-centric growth models that have characterized Indian state development policies.
Core Urban Region Economy (CURE) focuses on Hyderabad’s metropolitan area as the intellectual and innovation epicenter. This zone will host high-tech innovation clusters, digital health headquarters, and Global Capability Centers (GCCs) for multinational life sciences companies. The CURE strategy recognizes that frontier science requires concentrated expertise, world-class infrastructure, and proximity to research institutions.
Peri-Urban Region Economy (PURE) is dedicated to large-scale manufacturing clusters, logistics hubs, and advanced bioprocessing facilities. Located in a ring around the metropolitan core, PURE zones will provide the physical manufacturing capacity required for biologics, cell and gene therapies, and next-generation vaccines. This separation of innovation-intensive activities (CURE) from manufacturing-intensive operations (PURE) mirrors successful global models in Singapore, Boston, and the San Francisco Bay Area.
Rural Agriculture Region Economy (RARE) aims to strengthen the rural economy through precision fermentation, sustainable agriculture technologies, and agri-biotech applications. The explicit goal is doubling farmers’ incomes by 2030 while creating rural employment in high-value biological manufacturing. RARE zones represent an innovative approach to ensuring that advanced life sciences development benefits the entire state, not just urban centers.
Industries Minister D. Sridhar Babu emphasized during the policy launch: “We are not building islands of excellence. We are creating an integrated ecosystem where innovation, manufacturing, and agricultural prosperity reinforce each other.”
Infrastructure as Strategic Enabler
Supporting this regional architecture is a massive infrastructure investment program that includes:
- Regional Ring Road (Maniharam): A 350-kilometer expressway encircling Hyderabad to facilitate movement between CURE, PURE, and RARE zones
- High-speed mobility corridors: Dedicated freight and passenger routes connecting manufacturing clusters to ports and airports
- New airports across the state: Expanding air connectivity beyond Hyderabad to support decentralized development
- “Blue & Green Hyderabad” initiative: Restoration of thousands of ponds and creation of extensive park zones
- Net-Zero Telangana pathway: Comprehensive sustainability framework targeting carbon neutrality
The infrastructure program represents a recognition that world-class life sciences capabilities require world-class physical connectivity, environmental sustainability, and quality of life amenities to attract global talent.
The $25 Billion Investment Target: Ambition Meets Execution
The policy’s $25 billion investment target by 2030 is ambitious but grounded in demonstrated momentum. BioAsia 2026 itself catalyzed approximately $3 billion in trade and investment commitments, including:
Rx Propellant’s Genome Valley Campus: A ₹1,000 crore investment creating over 1 million square feet of advanced laboratory infrastructure over six years, with potential for 5,000 high-skilled jobs. This project alone represents the kind of large-format life sciences campus that can anchor an innovation ecosystem.
Tredence’s AI-Driven Healthcare Analytics Hub: A U.S.-based firm committing to 1,800 new roles, reaching 2,200 employees by 2027. This investment underscores Hyderabad’s emergence as a preferred location for AI-first healthcare technology development.
Vaksindo (JAPFA) Vaccine Production Facility: Indonesia’s interest in establishing animal health vaccine manufacturing capacity in Telangana demonstrates the state’s appeal beyond traditional pharmaceutical markets.
Opella Healthcare and Sanofi GCC Expansions: Major French pharmaceutical players deepening their Hyderabad footprint, particularly in digital R&D and global operations support.
These commitments span the value chain from basic research infrastructure to advanced manufacturing to digital analytics—precisely the integrated ecosystem the Next Gen policy envisions.
Frontier Sciences as Strategic Priority
Unlike previous policies that focused primarily on generic pharmaceuticals and biosimilars, the Next Gen Life Sciences Policy explicitly prioritizes “frontier sciences” including:
- Advanced cell and gene therapies: CAR-T, TCR-T, and next-generation gene editing platforms
- mRNA vaccine and therapeutic platforms: Building on India’s vaccine manufacturing leadership
- Precision fermentation and synthetic biology: Creating high-value biological compounds without traditional agriculture
- AI-native drug discovery platforms: Integrating computational biology from the start of the R&D process
- Digital health and connected diagnostics: Leveraging India’s digital infrastructure for healthcare delivery
This frontier focus signals Telangana’s intention to compete not just on cost and scale—where it already excels—but on innovation and technological sophistication. As Chief Minister Reddy stated: “We will not be satisfied being the world’s pharmacy. We will be the world’s laboratory.”
The GCC Strategy: From Back-Office to Innovation Engine
A particularly sophisticated element of the Next Gen policy is its explicit cultivation of Global Capability Centers as strategic innovation engines rather than cost centers. Telangana has recognized that multinational life sciences companies are fundamentally rethinking their global operating models, and Hyderabad is positioned to capture a disproportionate share of high-value GCC expansion.
The BioAsia 2026 GCC panel—featuring executives from Novartis, Takeda, Amgen, Olympus, and Sanofi—provided concrete evidence of this shift. Gail Horwood of Novartis described her Hyderabad team as an “integrated extension of global teams,” building LLM-based behavioral science tools for the U.S. market. Sanjay Patel of Takeda emphasized that Hyderabad is now a “flagship innovation location” for AI-driven research and quality management.
The policy creates specific incentives for GCCs that conduct R&D, file patents from India, and employ Ph.D.-level talent in computational biology and data science. This moves beyond traditional tax incentives to focus on activities that build long-term intellectual capital in the state.
The Hospital-Industry Innovation Bridge
Recognizing that technological breakthroughs must be validated in clinical settings, the policy framework includes strong support for the Research and Innovation Circle of Hyderabad (RICH) “Hospital-Industry Innovation Bridge” initiative launched at BioAsia 2026.
This structured ecosystem enables clinicians, medical students, researchers, and startups to collaborate in hands-on learning environments. By embedding clinical immersion pathways, the program accelerates translation of medtech and biopharma innovations into practical healthcare solutions validated by real-world clinical needs.
The Bridge addresses a critical gap in India’s innovation ecosystem: the disconnect between laboratory science and clinical application. Many promising technologies fail not because of scientific flaws but because they don’t address actual clinical workflows or patient needs. The Hospital-Industry Innovation Bridge ensures that innovation is grounded in clinical reality from the outset.
Vision 2047: The 22-Year Trajectory
While the Next Gen Life Sciences Policy has a 2030 horizon, it is explicitly positioned as Phase 1 of the broader “Telangana Rising Vision 2047″—a 22-year development trajectory targeting a $3 trillion state economy by India’s centenary of independence.
The Vision 2047 document outlines successive waves of capability development:
2026-2030: Establish top-five global life sciences hub status; achieve $25 billion in investments; create manufacturing and GCC infrastructure
2031-2038: Transition from execution hub to innovation origin; file significant patents from Telangana-based R&D; develop indigenous advanced therapy platforms
2039-2047: Achieve technology self-sufficiency in critical biological capabilities; establish Telangana-origin companies as global leaders; demonstrate Net-Zero sustainability model
This phased approach recognizes that building genuinely world-class life sciences capabilities is a multi-decade endeavor requiring sustained policy consistency, infrastructure investment, and talent development.
The Talent Pipeline Challenge
Perhaps the most critical challenge to realizing the Next Gen policy’s ambitions is talent. The life sciences industry faces a global shortage of professionals who blend deep biological expertise with data science, AI, and industrial engineering capabilities.
The policy addresses this through multiple mechanisms:
- Partnerships with premier research institutions: Leveraging relationships with CSIR labs, CCMB, and university research centers in Hyderabad
- Industry-academic collaboration programs: Creating direct pathways from graduate programs to industry positions
- Global talent attraction initiatives: Streamlined visa processes and quality-of-life investments to attract diaspora talent
- Upskilling and reskilling programs: Converting traditional pharmaceutical talent to biologics and advanced modalities expertise
Minister Sridhar Babu noted that the state’s education strategy is being reoriented to produce not just more life sciences graduates, but graduates with the interdisciplinary skills demanded by TechBio companies.
Regulatory Modernization and Ease of Doing Business
Recognizing that world-class infrastructure and talent are insufficient without streamlined regulatory processes, the Next Gen policy includes several regulatory modernization initiatives:
- Single-window clearance system: One interface for all state-level approvals
- Fast-track manufacturing licenses: For biosimilars and well-characterized biologics
- Data protection and privacy frameworks: Ensuring compliance with global standards for clinical data and patient information
- IP protection and technology transfer support: Facilitating licensing and commercialization of innovations
While many regulatory functions remain under central government authority, Telangana is maximizing the policy flexibility available at the state level to create a business-friendly environment without compromising safety or ethical standards.
Sustainability as Competitive Advantage
The “Net-Zero Telangana” commitment embedded in Vision 2047 is not merely environmental responsibility—it’s strategic positioning. Global pharmaceutical and biotechnology companies face increasing pressure from investors, regulators, and customers to demonstrate environmental sustainability.
By positioning Telangana as a location where companies can achieve their sustainability goals, the state creates a differentiated value proposition. The “Blue & Green Hyderabad” initiative—restoring water bodies and expanding green spaces—directly supports this positioning while improving livability for the workforce.
The policy includes incentives for companies adopting sustainable manufacturing practices, renewable energy usage, and circular economy principles in bioprocessing. This creates a potential competitive advantage as environmental, social, and governance (ESG) factors become increasingly important in corporate location decisions.
Comparisons and Context: Global Benchmarking
To assess the ambition and feasibility of Telangana’s targets, comparison with established global hubs is instructive:
Massachusetts (Boston/Cambridge): ~$20 billion annual life sciences economic output, 80,000+ direct jobs, and 1,200+ companies. Built over 40+ years with anchor institutions (MIT, Harvard, multiple teaching hospitals) and sustained venture capital availability.
Singapore: ~$15 billion annual biomedical sciences output, 25,000+ jobs. Built over 20 years through aggressive government investment in infrastructure and talent, with a focus on advanced manufacturing.
San Diego: ~$40 billion annual life sciences economic output, 60,000+ jobs, 1,400+ companies. Evolved over 35+ years leveraging research universities and an entrepreneurial culture.
Telangana’s $25 billion investment target (not annual output) over four years is aggressive but not implausible given India’s scale, cost advantages, and the accelerating pace of global supply chain diversification. The key differentiator will be execution quality and policy consistency over multiple election cycles.
Geopolitical Context: India’s Strategic Role
Telangana’s life sciences ambitions exist within a broader geopolitical context of supply chain diversification and strategic autonomy. The COVID-19 pandemic exposed vulnerabilities in concentrated pharmaceutical manufacturing, particularly dependence on China for active pharmaceutical ingredients.
India’s recognized strengths in vaccine manufacturing, generic pharmaceuticals, and emerging capabilities in biologics position it as a critical node in resilient global supply chains. The massive international participation at BioAsia 2026—delegations from the U.S., South Korea, Japan, Indonesia, and European nations—reflects this strategic importance.
Telangana’s policy explicitly positions the state to capture a disproportionate share of this “friend-shoring” and supply chain diversification. The combination of strong manufacturing capabilities, growing R&D sophistication, and political stability makes Hyderabad an attractive location for companies seeking alternatives to single-country dependence.
The EY-Parthenon Validation: Platform Thinking as Core Strategy
The Next Gen policy’s emphasis on “platform thinking” received authoritative validation from the EY-Parthenon report “Pharma’s New Architecture” launched at BioAsia 2026. The report argues that the future of biopharma belongs to organizations that build reusable discovery and manufacturing platforms rather than one-off products.
For India and Telangana specifically, the report identifies platform-based biologics capabilities as the critical next frontier. While India excels at small molecule generics and is building biosimilar capacity, the most significant value creation over the next decade will come from advanced modalities: antibody-drug conjugates (ADCs), bispecifics, RNA therapies, and CRISPR-based platforms.
Telangana’s policy prioritization of these modalities, combined with incentives for platform development rather than just facility construction, suggests strategic alignment with where the industry is heading rather than where it has been.
Risks and Critical Success Factors
Despite the comprehensive nature of the Next Gen policy, several risks and critical success factors warrant attention:
Policy Continuity Risk: Life sciences infrastructure takes years to build and longer to mature. Maintaining policy consistency across election cycles and political transitions is essential but challenging in democratic systems.
Talent Availability Risk: Even with aggressive training programs, the availability of multi-disciplinary talent with biology, data science, and engineering expertise remains a global constraint.
Regulatory Harmonization: While Telangana can optimize state-level processes, many critical regulatory functions remain with central authorities. Success requires effective state-center coordination.
Capital Access: While policy creates enabling conditions, actual investment decisions depend on risk-adjusted returns. Ensuring access to both debt and equity capital for life sciences ventures is critical.
Infrastructure Execution: The ambitious infrastructure program requires flawless project management, land acquisition, and coordination across multiple agencies—areas where Indian governance systems have historically struggled.
Execution as the Ultimate Test
The Next Gen Life Sciences Policy 2026-30 and Telangana Rising Vision 2047 represent one of the most comprehensive and ambitious regional life sciences development strategies announced anywhere in the world. The integration of urban innovation zones, peri-urban manufacturing clusters, and rural agri-biotech development into a coherent regional strategy is genuinely innovative.
The $25 billion investment target, 500,000 job creation goal, and top-five global hub aspiration are bold but not implausible given India’s scale, Telangana’s existing capabilities, and global supply chain dynamics.
However, as multiple speakers at BioAsia 2026 emphasized, the era of “TechBio” is defined not by vision but by execution. The critical questions are not whether Telangana has articulated a compelling strategy—it clearly has—but whether the state can maintain policy consistency, execute infrastructure projects efficiently, develop talent pipelines, and create an environment where global companies and innovative startups choose Hyderabad over competing locations.
The next four years will provide the answer. If Telangana delivers on even 70% of this policy’s ambitions, Hyderabad’s position as a global life sciences hub will be secure. If execution falters or policy commitment wavers, the opportunity may pass to other Indian states or other nations equally eager to capture life sciences growth.
As Chief Minister Reddy concluded his policy address: “We are not making promises—we are making commitments. And we will be judged not by the elegance of our policy documents, but by the jobs we create, the innovations we enable, and the global recognition we earn.”
The global life sciences community will be watching closely. Telangana has laid out a $3 trillion blueprint. Now comes the hard part: building it.
– Rashmi Kumari
